文献速递腹部介入技术与安全PETCT

氟18氟米索硝唑在评估肝细胞癌经导管动脉栓塞术后治疗诱导组织缺氧方面的局限性:一项前瞻性先导研究

Limitations of Fluorine 18 Fluoromisonidazole in Assessing Treatment-induced Tissue Hypoxia after Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Prospective Pilot Study.
PubMed 文献 · Radiol Imaging Cancer · 2022-01-01

这项单臂、单中心、前瞻性先导研究于2016年9月至2017年3月纳入5名男性肝细胞癌患者,在栓塞治疗前后行18F-FMISO PET/CT,计算肿瘤与肝脏比值(TLR)。最终分析4例患者5个肿瘤,治疗前中位TLR为0.97,治疗后为0.85,TLR变化与肿瘤无活力高度相关(Spearman相关系数0.87),但肝脏本底信号噪声比低限制了18F-FMISO在肝细胞癌中的应用。

要点

  • 18F-FMISO在肝细胞癌中的摄取范围窄,肝脏信号噪声比低,限制其临床应用。
  • 治疗前后TLR变化与肿瘤无活力高度相关(Spearman相关系数0.87)。
  • 该研究为先导研究,最终仅分析4例患者5个肿瘤,结果需审慎解读。

核心结论

  • 尽管TLR变化与治疗反应之间存在相关性,但18F-FMISO在肝脏中的低信号噪声比限制了其在肝细胞癌中的应用。

研究设计与样本

  • 单臂、单中心、前瞻性先导研究,纳入至少一个肿瘤直径≥1.5 cm且影像学或组织学诊断为肝细胞癌的参与者(5名男性,平均年龄68岁,年龄范围61-76岁)。
  • 参与者在肝细胞癌单纯栓塞治疗前后接受18F-FMISO PET/CT检查,计算肿瘤与肝脏比值(TLR)。
  • 最终分析纳入4例患者5个肿瘤,中位肿瘤直径3.2 cm(IQR 3.0-3.9 cm)。
  • 采用Wilcoxon秩和检验比较治疗前后平均TLR差异,采用Spearman秩相关系数评估TLR与肿瘤活力之间的相关性。

诊断标准与关键数值

  • 治疗前中位TLR为0.97(IQR 0.88-0.98),方差为0.02;治疗后中位TLR为0.85(IQR 0.79-1),方差为0.01,均提示18F-FMISO在肝细胞癌中的摄取范围窄。
  • TLR变化与肿瘤无活力之间的Spearman秩相关系数为0.87,提示高度相关。

临床应用与阅片要点

  • 原文结论指出,18F-FMISO在肝脏中的低信号噪声比限制了其在肝细胞癌中的应用。
  • 原文未据此给出推荐。

局限性

  • 原文结论指出18F-FMISO在肝脏中的低信号噪声比限制了其在肝细胞癌中的应用。
  • 本研究为先导研究,最终分析仅纳入4例患者5个肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine the variance and correlation with tumor viability of fluorine 18 (18F) fluoromisonidazole (FMISO) uptake in hepatocellular carcinoma (HCC) prior to and after embolization treatment. Materials and Methods In this single-arm, single-center, prospective pilot study between September 2016 and March 2017, participants with at least one tumor measuring 1.5 cm or larger with imaging or histologic findings diagnostic for HCC were enrolled (five men; mean age, 68 years; age range, 61-76 years). Participants underwent 18F-FMISO PET/CT before and after bland embolization of HCC. A tumor-to-liver ratio (TLR) was calculated by using standardized uptake values of tumor and liver. The difference in mean TLR before and after treatment was compared by using a Wilcoxon rank sum test, and correlation between TLR and tumor viability was assessed by using the Spearman rank correlation coefficient. Results Four participants with five tumors were included in the final analysis. The median tumor diameter was 3.2 cm (IQR, 3.0-3.9 cm). The median TLR before treatment was 0.97 (IQR, 0.88-0.98), with a variance of 0.02, and the median TLR after treatment was 0.85 (IQR, 0.79-1), with a variance of 0.01; both findings indicate a narrow range of 18F-FMISO uptake in HCC. The Spearman rank correlation coefficient was 0.87, indicating a high correlation between change in TLR and nonviable tumor. Conclusion Although there was a correlation between change in TLR and response to treatment, the low signal-to-noise ratio of 18F-FMISO in the liver limited its use in HCC. Keywords: Molecular Imaging-Clinical Translation, Embolization, Abdomen/Gastrointestinal, Liver Clinical trial registration no. NCT02695628 © RSNA, 2022.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Shah RP, Laeseke PF, Shin LK, et al. Limitations of Fluorine 18 Fluoromisonidazole in Assessing Treatment-induced Tissue Hypoxia after Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Prospective Pilot Study. Radiol Imaging Cancer. 2022. PMID: 35485937. doi:10.1148/rycan.210094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。